![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » PALATIN COMPLETES ENROLLMENT IN PT-141 TRIALS FOR FEMALE SEXUAL DYSFUNCTION AND MALE ERECTILE DYSFUNCTION
PALATIN COMPLETES ENROLLMENT IN PT-141 TRIALS FOR FEMALE SEXUAL DYSFUNCTION AND MALE ERECTILE DYSFUNCTION
Palatin Technologies has completed enrollment in separate Phase IIa clinical trials evaluating PT-141 in patients experiencing female sexual dysfunction (FSD) and male erectile dysfunction (ED).
The FSD clinical trial was designed to evaluate the safety and efficacy of PT-141 in premenopausal women with a diagnosis of FSD. The ED clinical trial was designed to evaluate the safety and efficacy of PT-141 co-administered with sildenafil (Viagra) in men with a diagnosis of ED.
The company is currently analyzing the data for both in-clinic trials and plans to release the results later this quarter. PT-141 is Palatin's lead drug candidate for the treatment of male and female sexual dysfunction and is being jointly developed in collaboration with King Pharmaceuticals.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct